Mangoceuticals (MGRX) Cost of Revenue (2023 - 2026)

Mangoceuticals has disclosed Cost of Revenue across 4 years of filings, most recently posting $10437.0 for Q2 2026.

• In Q2 2026, Cost of Revenue fell 44.53% year-over-year to $10437.0; the TTM figure through Jun 2026 stood at $29525.0 (down 65.82% YoY), while the FY2025 annual figure was $54422.0, down 41.67% from the prior year.
• Cost of Revenue came in at $10437.0 for Q2 2026 at Mangoceuticals, up from $8218.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $53362.0 in Q4 2023 to a low of $2359.0 in Q3 2025.
• Average Cost of Revenue over 4 years is $22948.1, with a median of $21418.0 recorded in 2024.
• The largest YoY upside for Cost of Revenue was 18.96% in 2025 against a maximum downside of 89.03% in 2025.
• Over 4 years, Cost of Revenue stood at $53362.0 in 2023, then tumbled by 60.03% to $21331.0 in 2024, then plunged by 60.1% to $8511.0 in 2025, then grew by 22.63% to $10437.0 in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $10437.0 in Q2 2026, $8218.0 in Q1 2026, and $8511.0 in Q4 2025.